Pharmaceutical Companies Developing Drugs to Target Lp(a) Cholesterol for Heart Attack Prevention
Novartis, Amgen, and Eli Lilly are developing drugs to lower Lp(a) cholesterol, a genetic risk factor for heart attacks. These companies are in late-stage trials to determine if reducing Lp(a) can prevent heart attacks, with results expected later this year. The potential market is large, as one in five people globally have elevated Lp(a) levels.
Topics: clinical trials heart attack prevention Lp(a) cholesterol pharmaceutical research